Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4

Researchers sought to analyze the estimated cost per treated patient, cost per complete responder, and cost per month in progression-free survival (PFS) for ciltacabtagene autoleucel (cilta-cel), a chimeric antigen receptor T-cell therapy approved for patients with relapsed/refractory multiple myeloma. The total cost per treated patient, total cost per complete responder, and total cost per month in PFS were estimated at $704,641, $963,941, and $30,978 for cilta-cel, respectively, and $840,730, $3,856,559, and $42,520 for standard of care (daratumumab plus pomalidomide and dexamethasone or pomalidomide plus bortezomib and dexamethasone) over a 25.4-month period.